The Imidazacridine Derivative LPSF/AC-05 Induces Apoptosis, Cell Cycle Arrest, and Topoisomerase II Inhibition in Breast Cancer, Leukemia, and Lymphoma
Authors:
- Mardonny Bruno de Oliveira ChagasMCMardonny Bruno de Oliveira Chagas
- Claudio MontenegroCMClaudio Montenegro
- Michelle Melgarejo da RosaMRMichelle Melgarejo da Rosa
- Michelly Cristiny PereiraMPMichelly Cristiny Pereira
- Moacyr Jesus Barreto de Melo RegoMRMoacyr Jesus Barreto de Melo Rego
- Maira Galdino da Rocha PittaMPMaira Galdino da Rocha Pitta
- 1 February 2025
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 25 (5) , 431-444
Abstract
Introduction: Cancer is one of the major causes of morbidity and mortality worldwide. Current treatments for both solid and hematological tumors are associated with severe adverse effects and drug resistance, necessitating the development of novel selective antineoplastic drugs Methods: The present study describes the antitumor activity of the imidazacridine derivative 5-acridin-9-ylmethylidene-2-thioxoimidazolidin-4-one (LPSF/AC05) in breast cancer, leukemia, and lymphoma cells. Cytotoxicity assays were performed in PBMC and in breast cancer, leukemia, and lymphoma cell lines using the MTT method. Changes in cell cycle progression and apoptosis were assessed using flow cytometry. Moreover, topoisomerase II inhibition assays were performed. LPSF/AC05 exhibited cytotoxicity in six of the nine cell lines tested. Results: The best results for leukemia and lymphoma were observed in the Toledo, Jurkat, and Raji cell lines (IC50 = 27.18, 31.04, and 33.36 M, respectively). For breast cancer, the best results were observed in the triple-negative cell line MDA-MB-231 (IC50 = 27.54 μM). The compound showed good selectivity, with no toxicity to normal human cells (IC50 > 100M; selectivity index > 3). Cell death was primarily induced by apoptosis in all cell lines. Furthermore, LPSF/AC05 treatment induced cell cycle arrest at the G0/G1 phase in leukemia/lymphoma and at the G2/M phase in breast cancer. Finally, topoisomerase II was inhibited. Conclusion: These results indicate the potential application of LPSF/AC05 in cancer therapy.Keywords
Funding Information
- Brazilian National Council for Scientific and Technological Development (200052/2024-1)
- FACEPE, Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco (APQ-0898-4.03/15)
This publication has 86 references indexed in Scilit:
- Progress and promise of alternative animal and non-animal methods in biomedical researchArchives of Toxicology, 2023
- Mechanisms of cancer cell death induction by paclitaxel: an updated reviewApoptosis, 2022
- Tacrolimus Induces Apoptosis in Leukemia Jurkat Cells through Inactivation of the Reactive Oxygen Species-dependent Phosphoinositide-3-Kinase/Akt Signaling PathwayBiotechnology and Bioprocess Engineering, 2022
- Synthesis and Cytotoxicity of Diarylpentanoids against Sensitive CCRF‐CEM and Multidrug‐Resistant CEM/ADR5000 Leukemia CellsChemistry & Biodiversity, 2021
- Bispecific antibodies for the treatment of lymphomas: Promises and challengesHematological Oncology, 2021
- The ever‐increasing importance of cancer as a leading cause of premature death worldwideCancer, 2021
- Polatuzumab Vedotin: First Global ApprovalDrugs, 2019
- Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1‐involved pathwayCancer Medicine, 2019
- Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poisonBiochemical and Biophysical Research Communications, 2014
- Chemotherapeutic potential of 9-phenyl acridine: biophysical studies on its binding to DNAEuropean Biophysics Journal, 2010